title: Effects of a single contraceptive Silastic implant containing nomegestrol acetate on ovarian function and cervical mucus production during 2 years.
abstract: OBJECTIVE
  To study the mechanism of action of Uniplant (South to South Corporation in Reproductive Health, Salvador, Brazil), a single Silastic capsule containing nomegestrol acetate (Lutenyl, Theramex, France) in women during 2 years.
  
  
  METHODS
  Comparison between the hormonal levels, follicular development, cervical mucus (CM) production, and endometrial thickness in the menstrual cycle before implant insertion and at 1, 6, 12, 18, and 24 months after implant insertion.
  
  
  METHODS
  A total of 15 women of reproductive age were enrolled for the 1st year of use. Twelve of these women continued for a 2nd year of Uniplant use.
  
  
  METHODS
  Hormonal plasma levels were measured in control cycles and at 1, 6, 12, 18, and 24 months of Uniplant use. Cervical mucus, follicular development, and endometrial thickness also were evaluated.
  
  
  RESULTS
  In this study, Uniplant blocks ovulation in 86 percent of cycles studied. Disturbances in follicular growth were observed also. Cervical mucus was scanty and viscous in all women during this study. Endometrial thickness was <8 mm in all cycles studied.
  
  
  CONCLUSIONS
  This study shows that Uniplant is a long-acting contraceptive that probably acts at the hypothalamic-pituitary levels, on the ovary, on CM production, and on the endometrium. These properties suggest the use of Uniplant as a contraceptive agent, especially if one considers the lack of androgenic and metabolic effects and the maintenance of periodic bleeding similar to menstruation.
authors.affiliation: Federal University of Bahia, Maternidade Climério de Oliveira, Salvador, Brazil.
authors.forename: I
authors.initials: I
authors.lastname: Barbosa
authors.forename: E
authors.initials: E
authors.lastname: Coutinho
authors.forename: C
authors.initials: C
authors.lastname: Hirsch
authors.forename: O
authors.initials: O
authors.lastname: Ladipo
authors.forename: S E
authors.initials: SE
authors.lastname: Olsson
authors.forename: U
authors.initials: U
authors.lastname: Ulmsten
mesh_terms: D000293:Adolescent; D000328:Adult; D002582:Cervix Mucus / Q000187:drug effects* / Q000378:metabolism*; D003271:Contraceptive Agents, Female / Q000008:administration & dosage*; D004343:Drug Implants; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008535:Megestrol; D008597:Menstrual Cycle / Q000187:drug effects; D009649:Norpregnadienes / Q000008:administration & dosage*; D010053:Ovary / Q000187:drug effects* / Q000502:physiology*; D011374:Progesterone / Q000097:blood; D045167:Progesterone Congeners / Q000008:administration & dosage*; D012738:Sex Hormone-Binding Globulin / Q000378:metabolism; D012826:Silicone Elastomers; D013997:Time Factors
chemical_list: D003271:Contraceptive Agents, Female; D004343:Drug Implants; D009649:Norpregnadienes; D045167:Progesterone Congeners; D012738:Sex Hormone-Binding Globulin; D012826:Silicone Elastomers; D011374:Progesterone; D004958:Estradiol; C038501:nomegestrol acetate; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D008535:Megestrol